Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: August 17, 2011
Last updated: May 17, 2016
Last verified: May 2016

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients.

PURPOSE: This research trial is studying proteins that may promote chemotherapy resistance in samples from patients with acute myeloid leukemia.

Condition Intervention
Genetic: protein expression analysis
Other: flow cytometry
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Changes in Stat3 and Stat5 in paired diagnostic and relapsed AML samples
  • Reduction in chemotherapy sensitivity by relapsed samples compared to diagnostic samples

Estimated Enrollment: 40
Study Start Date: September 2011
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • Investigate whether changes in prosurvival signaling occur by comparing activation of the signal transducer and activator of transcription-3 (Stat3) and Stat5 pathways in paired diagnostic and relapse samples.
  • Investigate changes in leukemia cell responses to extrinsic cues from the environment change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance.

OUTLINE: Cryopreserved samples are analyzed for Stat3 and Stat5 expression by flow cytometry and in vitro chemotherapy sensitivity.


Ages Eligible for Study:   up to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute myeloid leukemia


  • Paired diagnostic and relapsed cryopreserved samples from patients with acute myeloid leukemia


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01419496

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Michele S. Redell, MD, PhD Texas Children's Cancer Center
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01419496     History of Changes
Other Study ID Numbers: AAML12B1
COG-AAML12B1 ( Other Identifier: Children's Oncology Group )
AAML12B1 ( Other Identifier: Children's Oncology Group )
NCI-2011-02984 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Study First Received: August 17, 2011
Last Updated: May 17, 2016

Keywords provided by Children's Oncology Group:
recurrent adult acute myeloid leukemia
recurrent childhood acute myeloid leukemia
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
adult acute myeloid leukemia with del(5q)

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms processed this record on April 27, 2017